The focus of our rare neuromuscular franchise is primary periodic paralysis. Our commercial effort is on KEVEYIS, the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis.
Primary periodic paralysis (PPP) is a genetic, neuromuscular disorder that can cause extreme muscle weakness and/or paralysis. It often interferes with daily activities and, as patients get older, it can lead to permanent muscle weakness. Primary periodic paralysis may be localized (“focal”) or more widespread (“generalized”), and it often goes underdiagnosed and/or undertreated. The 2 most common forms of this disorder are “hyperkalemic” and “hypokalemic” periodic paralysis.1-6
For KEVEYIS important safety information, please see full Prescribing Information (PDF).
The focus of our rare endocrine franchise is on both Cushing’s syndrome and acromegaly. Our clinical effort is on developing new therapies to treat these rare endocrine disorders.
Endogenous Cushing’s syndrome, characterized by sustained elevated cortisol levels, presents unique clinical challenges to patients and healthcare providers.
Acromegaly can be difficult to diagnose, and difficult to treat. Patients with acromegaly face numerous health issues related to their condition, and have limited treatment options available.
The safety and efficacy of RECORLEV™ (levoketoconazole) and veldoreotide have not been established.
KEVEYIS® is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.7
In clinical studies, the most common side effects of KEVEYIS were a numbness or tingling, difficulty thinking and paying attention, changes in taste, and confusion. These are not all of the possible side effects that you may experience with KEVEYIS. Talk to your doctor if you have any symptoms that bother you or do not go away.
KEVEYIS is not for everyone. Do not take KEVEYIS if you:
Taking KEVEYIS may cause a drop in the amount of potassium (an electrolyte) in your body, which can lead to heart problems. Ask your doctor if you need to eat foods that contain high amounts of potassium while taking KEVEYIS.
Your body may produce too much acid or may not be able to remove enough acid from body fluids while taking KEVEYIS. Your doctor will run tests on a regular basis to check for signs of acid buildup and may reduce your dose or stop your treatment with KEVEYIS.
KEVEYIS may also increase the risk of falls, especially in elderly patients and patients taking high doses of KEVEYIS. Use caution when driving, operating machinery, or performing any other hazardous activities while taking KEVEYIS, as this medication may cause drowsiness.
For additional KEVEYIS important safety information, please see full Prescribing Information (PDF).
© 2017 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA™ is a trademark of Strongbridge Biopharma plc.
KEVEYIS® is a registered trademark licensed exclusively in the US to Strongbridge Biopharma plc.
MLR010 V7 12/2016